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Clearly it is essential to have an organized, experi-
enced team in place. One needs an energetic endo-
scopist, an aggressive surgeon; a capable anesthesio-
logist and the rest of the supporting cast to undertake
prompt diagnostic procedures, perform major surgery
quickly, to provide nutritional support and to carry the
patient through the post-operative period and a long
term follow-up.
Despite all this praise, Orloffis not perfect. He makes
the point that he is using the Child-Turcotte-Campbell
system of grading the severity of cirrhosis 7, but he is
not. In the Campbell modification it is necessary to
determine whether the ascites is "easily controlled" or
"difficult to control", decisions that require multiple
observations. In Orloff’s series ascites is graded on its
preserved absence and volume immediately after a dis-
cussion. Furthermore, there are better methods of
treating active bleeding than by infusing vasopressin.
One aspect of these data must be taken into serious
consideration, i.e. "The Wizard Phenomenon". A wiz-
ard is defined as "one endowed with exceptional
skill...and able to achieve something held to be im-
possible’’9. Orloff’s reported feats with EPCS surgery
easily satisfy this definition. One must worry whether
subsequent surgeons can equal Orloff’s achievements,
but this lis the way of the world. In all fields ofhuman
endeavor progress is made by incremental break-
throughs. On October 18, 1968, for example Bob Be-
amon made a prodigious longjump at the Olympics is
Mexico City (8.90 m), almost 22 inches, longer than the
existing world record, which had changed less than
8 inches in 33 years. In 1991, this new record, too, was
broken o. Starzl et al., performed the first liver trans-
plant in a human in 1963 a unique occurrence thought
then to be of little practical value, and now, thirty years
later, this procedure is performed as standard therapy
at hundreds of hospitals. EPCS has been performed by
many surgeons formany years, perhaps, not so success-
fully as Orloff, but I predict that using a different time
frame, surgeons will be able to perform this procedure
as rapidly and effectively as the Wizard of San Diego.
After considering all these data I think that EPCS
may be the one true treatment of actively bleeding
varices and that Orloff is its prophet.
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THE ROLE OF THE DISTAL SPLENORENAL SHUNT
IN THE SCLEROTHERAPY ERA?
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Between September 1982 and April 1988, 60 Cirrhotic patients with prior variceal
hemorrhage were randomized to undergo the placement of an elective shunt (distal
splenorenal: 26; nonselective: 4) or long-term endoscopic sclerotherapy (n--30). Eighty-
six percent of patients had alcoholic cirrhosis, and 33% were classified as Child’s class C.
After a mean follow-up of87 months, 60% ofpatients undergoing sclerotherapy and 17%
ofshunt patients experienced rebleeding (p < 0.001). Shunt patients have survived longer
than those who had sclerotherapy (6-year survival rates of 53% and 26%, respectively;
p < 0.05). In part because of the wide geographic distribution of patients, only 4 of 13
patients in whom sclerotherapy failed (31%) could undergo salvage by shunt surgery.
Although hepatic portal perfusion was better maintained after sclerotherapy, there
were no major differences between the groups in terms of post-therapy hepatic or
psychoneurologic function.
In a predominantly alcoholic cirrhotic patient population (half non-urban), the results
of elective shunt surgery were superior to those of chronic endoscopic sclerotherapy with
respect to the prevention of recurrent variceal hemorrhage and survival.
KEY WORDS: Distal splenorenal shunt, sclerotherapy, portal hypertension,
oesophageal varices, variceal bleeding, cirrhosis
PAPER DISCUSSION
In the 1990’s, endoscopic sclerosis of esophageal vari-
ces and decompressive shunts are two of the many
therapies required to provide optimum management
of patients with variceal bleeding. This paper from
Rikkers and his colleagues is an important contribu-
tion in helping to define the places of these therapies.
This prospective randomized controlled trial reports
the status of all patients entered, has a mean 7 year
follow up, and presents objective data. As such, it should
receive a heavy positive weighting in consideraation of
studies for management of variceal bleeding. What are
the major lessons it teaches us?
The patient population is an important factor in
outcome and therapy choice. Two features of the pa-
tient population in this study influence the outcome.
Eighty seven percent of patients randomized had alco-
holic cirrhosis, and 57% of those who survived more
than 3 months returned to drinking. Outcome is appli-
cable to this group of patients, and should not be
extrapolated to patients with other etiologies of their
portal hypertension. In addition, this study was con-
ducted in two geographic locations with a wide disper-
sion of patients in each location. In the group
randomized to sclerotherapy geographic factors prob-
ably played a role in outcome in that 27% died of
rebleeding, with delayed access to "surgical rescue"
playing a role in that mortality. The lesson: scler-
otherapy is not a good choice for those who live in
remote locations with poor access to medical care.
Long-term management of variceal bleeding with
sclerotherapy is associated with a high risk of rebleeding.
In this study, with 7 year follow up, 60% of patients
rebleed through sclerotherapy with 43% of the total
group failing sclerotherapy. This failure was defined as
death from rebleeding or the need for surgery for bleed-
ing. This observation is consistent with other randomiz-
ed studies in which sclerotherapy has been a treatment
option and in which there is long-term follow up
(1,2, 3). While the greatest risk of rebleeding through
sclerotherapy is early in the course--the risk never
goes away. In this study the authors do further empha-
size that the later rebleeding is frequently from gastric
varices or portal hypertensive gastropathy. In contrast,
decompressive shunt provides significantly better con-
trol of bleeding, which in this study translated to an
improved survival. The lessons: i) rebleeding through
sclerotherapy is about 50% at 5 years, and ii) preven-
tion ofrebleeding is one variable in improving survival.
Liver function and encephalopathy were carefully
followed in this study. Quantita-tive liver function
measured by galactose elimination capacity and in-
docyanine green clearance, and hepatic encephalo-
pathy measured by clinical, psychometric and ele-
ctroencephalographic studies were not significantly
different in the two randomized groups. While at first
sight one is tempted to say that the disadvantages of
rebleeding through sclerotherapy and loss of portal
perfusion in some of the shunt patients offset each
other, this does not really appear to be the case. No
patients had severe disabling encephalopathy, and theHPB INTERNATIONAL 67
quantitative measures of liver function remained good.
These data are consistent with our own study compar-
ing DSRS and sclerotherapy which measured quan-
titative liver function. We showed that patients
successfully managed with sclerotherapy, who had no
major rebleeding, showed a significant improvement in
galactose elimination capacity over the first year 1.
Lesson: the data in this study show that neither of the
randomized therapies significantly accelerate liver fail-
ure compared to each other.
What of the high mortality and failure to achieve
surgical rescue of patients who failed sclerotherapy in
this study? This factor is the major difference between
this study and our previously published study. In the
Emory study only one patient randomized to scler-
otherapy died as a direct result of rebleeding, and 12
were successfully salvaged by surgical management. In
contrast, in the present study 8 patients died as a direct
result of rebleeding in the sclerotherapy group and
only 5 patients had surgical rescue. The authors cor-
rectly point out that access was a major problem for
their sclerotherapy patients who rebleed, and this high-
lights one of the shortcomings of sclerotherapy. What
are the lessons? In patients in whom sclerotherapy is
selected as primary management, a strategy should be
in place from the outset to treat rebleeding or consider
surgical treatment for persistent high risk varices.
Finally, it must be remembered that sclerotherapy
and surgical shunt are not the only treatments for
variceal bleeding. Liver transplant has dramatically
altered the management of patients with end-stage
liver disease. But, it is end-stage liver disease and not
variceal bleeding per se which is the indication for
transplant. However, in any patient who bleeds from
varices, full evaluation at the time of the initial bleed is
a critical step to help answer the question: is this
patient now, or will they in the future be a candidate for
liver transplant? The answer to that question will
influence treatment choice.We have recently published
an approach to the evaluation of such patients’. In
addition, the radiologists are back in the fray 5. Trans-
jugular intrahepatic portal system shunts (TIPS) can
provide portal decompression, but lack ofrandomized
trials and good objective data leave the role ofTIPS to
be defined.
In summary, the four prospective randomized trials
which have compared DSRS to sclerotherapy all show
better control of bleeding with decompressive shunt6.
Neither therapy appears to significantly accelerate
liver failure. Survival differs in these studies, and the
difference depends entirely on how patients who fail
sclerotherapy are managed. The important factors in
this are the type of patient, their access to care, and the
type of care available to the patient. To the physician
making management decisions, forward planning with
these factors in mind is the key.
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